Fig. 6. (A ) Microscopic view (×10) of mouse hippocampal slices labeled with propidium iodide during preconditioning challange. OGD = 60 min of oxygen and glucose deprivation; Dex = dexmedetomidine: 10−6m; PD = PD 098059: 5 μm; PP2 = Src kinases inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (5 μm). (B ) Effects of the α2-adrenoceptors inhibitor yohimbine (yoh: 100 μm), the Src kinases inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2, 5 μm), the inhibitor of the PI3-Kinase wortmanin (Wort: 100 nm), and their combination on dexmedetomidine-related preconditioning against 60 min of OGD in the CA1 subfield area. Data (mean ± SD) are expressed as a percentage of fluorescence intensity from control (control: 100%). ANOVA for PI fluorescence was F = 184, P < 0.0001. Post hoc analysis used Bonferroni correction. NS = nonsignificant; ***P < 0.0001 versus control; ♦♦♦P < 0.001 versus 60 min of OGD. Effects of the imidazoline receptors antagonist 1 efaroxan (Efa: 10 μm), the MEK inhibitor PD 098059 (PD: 5 μm), and the mitochondrial ATP-dependant K channel 5-hydroxydecanoic acid (5HD: 10 μm) on dexmedetomidine-related preconditioning against 60 min of OGD (OGD in the CA1 subfield area). Data (mean ± SD) are expressed as fluorescence intensity increase from control (control: 100%). ANOVA for PI fluorescence was F = 156.3, P < 0.0001. Post hoc analysis used Bonferroni correction. NS = nonsignificant; ***P < 0.001 versus control; ♦♦♦P < 0.001 versus 60 min of OGD.